Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Hold Zydus Lifesciences: target of Rs 405: ICICI Direct

ICICI Direct recommended hold rating on Zydus Lifesciences with a target price of Rs 405 in its research report dated August 13, 2022.

August 16, 2022 / 05:55 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

ICICI Direct's research report on Zydus Lifesciences

Zydus is a leading pharma company with family pedigree having a presence in domestic branded formulations, US generics and is in the process of repurposing itself into niche areas of specialty pharmaceuticals, biosimilars and vaccines. FY22 revenue break-up – US: 39%, India: 32%, Wellness: 13%, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa: 10% • Zydus is the fourth largest pharma company in India with 14 brands among Top 300 pharma brands in India and nine with Rs 100 crore+ sales.

Outlook

We maintain HOLD rating as we wait for 1) consistency from US business in terms of continued traction in base business, new launches and steadiness in price erosion besides pending cGMP resolution. We value Zydus Lifesciences at Rs 405 (base business of Rs 381 at 16x P/E on FY24E EPS of Rs 23.8 + NPV of Rs 26.7 for gRevlimid opportunity).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Zydus Lifesciences - 140822 - ic

Broker Research
first published: Aug 16, 2022 05:55 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347